Tags : Amgevita (adalimumab

Amgen Collaborates with Orion for Commercialization of Amgevita (adalimumab, biosimilar)

Shots: Amgevita is indicated to treat chronic inflammatory diseases such as moderate-to-severe RA, IBD and psoriasis Amgen Biosimilar Amgevita, is a novel adalimumab’s biosimilar to be marketed in Finland. On 23 Mar, 2017 Amgevita received EU approval for inflammatory diseases in adults In 2013, Orion marketed first infliximab’s biosimilar in Finland post its marketing approval. […]Read More